News: Basilea

News

News Subscription

Dec 03. 2013

Basilea reports that isavuconazole receives Qualified Infectious Disease Product (QIDP) designation from U.S. FDA for the treatment of invasive aspergillosis

Read more

Nov 18. 2013

Basilea reports isavuconazole orphan drug designation for treatment of zygomycosis by U.S. FDA

Read more

Nov 04. 2013

Basilea appoints new Chief Financial Officer

Read more

Oct 23. 2013

Basilea's antibiotic ceftobiprole obtains regulatory approval in Europe for pneumonia

Read more

Sep 30. 2013

Basilea reports positive topline phase 3 results for antifungal isavuconazole

Read more

Sep 16. 2013

Swissmedic accepts for review Basilea's ceftobiprole Marketing Authorization Application for the treatment of pneumonia

Read more

Sep 13. 2013

Basilea reports presentation of 19 posters at ICAAC on investigational anti-infectives isavuconazole, ceftobiprole, and BAL30072

Read more

Aug 21. 2013

Basilea reports 2013 half-year financials with improved operating results

Read more

Jul 17. 2013

Basilea provides update on isavuconazole phase 3 program

Read more

Jun 25. 2013

Basilea awarded contract by BARDA of up to USD 89 million for the development of its novel antibiotic BAL30072

Read more

previous
1
…
30
31
32
next